A Phase II Study of Ibrutinib in Combination With Rituximab-Cyclophosphamide-Doxorubicin Hydrochloride-Vincristine Sulfate-Prednisone Therapy in Epstein-Barr Virus-Positive, Diffuse Large B Cell Lymphoma (54179060LYM2003: IVORY Study): Results of the Final Analysis
Annals of Hematology - Germany
doi 10.1007/s00277-020-04005-6
Full Text
Open PDFAbstract
Available in full text
Date
April 24, 2020
Authors
Publisher
Springer Science and Business Media LLC